Key result
Elevated high-sensitivity troponin T was associated with an increased risk of cardiovascular death (AHR 3.07; 95% CI 2.35-4.02; P<.001) in patients with type 2 diabetes.
Why the study?
Does the assessment of biomarkers (hs-TnT, NT-proBNP, hs-CRP) provide incremental prognostic value beyond clinical variables for cardiovascular risk stratification in patients with type 2 diabetes?
RCT (n=16,492)
double-blind
Randomization to saxagliptin vs placebo
Does the assessment of biomarkers (hs-TnT, NT-proBNP, hs-CRP) provide incremental prognostic value beyond clinical variables for cardiovascular risk stratification in patients with type 2 diabetes?
Effect estimate: AHR 3.07 (95% CI 2.35-4.02)
p-value: p=<.001
In patients with type 2 diabetes at high cardiovascular risk, elevated levels of hs-TnT, NT-proBNP, and hs-CRP provide incremental prognostic value beyond traditional clinical variables for predicting cardiovascular events.
No takes yet. Share an insight, caveat, or question.
hs-TnT may aid risk stratification in type 2 diabetes beyond clinical variables; leaves open prospective validation and therapeutic impact.
Scirica et al. (2016) conducted an RCT in type 2 diabetes with overt cardiovascular disease (CVD) or multiple risk factors (n=16,492). saxagliptin vs. placebo was evaluated on Cardiovascular death (associated with elevated high-sensitivity troponin T) (AHR 3.07, 95% CI 2.35-4.02, p=<.001). Elevated high-sensitivity troponin T was associated with an increased risk of cardiovascular death (AHR 3.07; 95% CI 2.35-4.02; P<.001) in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: